Biotech Australia news - Labiotech.eu

Australian biopharma Telix banks on AI with Dedicaid acquisition

Jim Cornall — Thu, 27 Apr 2023 11:08:27 +0000

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […]

The post Australian biopharma Telix banks on AI with Dedicaid acquisition appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Jim Cornall — Tue, 28 Feb 2023 11:09:36 +0000

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]

The post Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer appeared first on Labiotech.eu.

Certa scleroderma study shows improvement in more than 60% of patients

Jim Cornall — Tue, 07 Feb 2023 09:45:55 +0000

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

The post Certa scleroderma study shows improvement in more than 60% of patients appeared first on Labiotech.eu.

Computational chemistry and cancer

External Contributor — Wed, 01 Feb 2023 07:08:00 +0000

by Martin Slater, Cresset Discovery Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological testing to provide a complete and reliable picture of a target system. This is perhaps no better illustrated than in Cresset Discovery’s project with University of South Australia, which […]

The post Computational chemistry and cancer appeared first on Labiotech.eu.

Cartherics granted first patent in China

Jim Cornall — Mon, 09 Jan 2023 10:30:46 +0000

Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […]

The post Cartherics granted first patent in China appeared first on Labiotech.eu.

Pictor receives $5M in funding for Covid antibody test and human and animal portfolios

Liza Laws — Tue, 06 Dec 2022 12:04:22 +0000

Pictor, a global leader in immunodiagnostics, has announced a $5 million funding round to help accelerate pipeline product development projects. The company will also use the funding for market development activities within Australia and New Zealand, the U.S. and Europe for its human health and animal health portfolios. This follows a June funding round raising […]

The post Pictor receives $5M in funding for Covid antibody test and human and animal portfolios appeared first on Labiotech.eu.

LAG-3: The next big checkpoint inhibitor target

Jonathan Smith — Tue, 29 Nov 2022 17:44:17 +0000

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]

The post LAG-3: The next big checkpoint inhibitor target appeared first on Labiotech.eu.

BIA and Exopharm sign joint research agreement to develop integrated technology

Liza Laws — Wed, 23 Nov 2022 19:03:26 +0000

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

The post BIA and Exopharm sign joint research agreement to develop integrated technology appeared first on Labiotech.eu.

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

Jim Cornall — Tue, 08 Nov 2022 08:19:05 +0000

The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […]

The post Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma appeared first on Labiotech.eu.

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Jim Cornall — Tue, 08 Nov 2022 07:57:08 +0000

Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89 Zr- DFO-girentuximab). The ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) has met its co-primary and secondary endpoints. The study results delivered 86% sensitivity and […]

The post Telix Pharmaceuticals sees positive results in kidney cancer imaging study appeared first on Labiotech.eu.

The hottest private biotech companies in Australia

Jonathan Smith — Tue, 18 Oct 2022 15:49:32 +0000

Australia has a strong base in biotechnology, with many incentives for R&D and commercialization. Here are the top five private Australian biotech companies that have recently showcased the country’s credentials in the sector. Australia is a highly developed nation in the Southern Hemisphere. Famous for its huge wool trade and iron ore wealth, the country […]

The post The hottest private biotech companies in Australia appeared first on Labiotech.eu.

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

Jim Cornall — Fri, 14 Oct 2022 07:31:15 +0000

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

The post A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation appeared first on Labiotech.eu.

Adalta and GPCR Therapeutics to collaborate on novel cancer treatments

Jim Cornall — Thu, 13 Oct 2022 08:39:29 +0000

AdAlta Limited and GPCR Therapeutics Inc, are set to collaborate to evaluate AdAlta’s CXCR4 inhibiting i‑bodies as cancer therapeutics, using GPCR Therapeutics’ combination inhibition approach. AdAlta said its i-body platform is suited to engaging an important class of drug targets called G-protein coupled receptors (GPCRs). One of these GPCRs is known as CXCR4. In addition […]

The post Adalta and GPCR Therapeutics to collaborate on novel cancer treatments appeared first on Labiotech.eu.

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

Liza Laws — Mon, 26 Sep 2022 14:03:03 +0000

A toxicology facility with more than 10,000 sq ft of laboratory space has opened in Australia and will help Agilex Biolabs expand its capacity to serve the biotech, pharma and animal health industries. After more than 25 years in the industry, Agilex Biolabs says it will now be able to share with an even more […]

The post Australian Agilex Biolabs expands its capacity with new toxicology testing facility appeared first on Labiotech.eu.

Study data for glioblastoma treatment confirms safety and tolerability profile

Liza Laws — Thu, 22 Sep 2022 18:09:43 +0000

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]

The post Study data for glioblastoma treatment confirms safety and tolerability profile appeared first on Labiotech.eu.

Emyria starts program with neuroscience drug discovery CRO

Jim Cornall — Thu, 22 Sep 2022 16:06:17 +0000

Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenic’s drug discovery platform, SmartCube. SmartCube extracts and analyzes behavioral and […]

The post Emyria starts program with neuroscience drug discovery CRO appeared first on Labiotech.eu.

Pancreatic cancer study using dual-cell therapy yields positive results

Jim Cornall — Wed, 14 Sep 2022 13:20:52 +0000

Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […]

The post Pancreatic cancer study using dual-cell therapy yields positive results appeared first on Labiotech.eu.

Starpharma announces new data for prostate cancer trial

Jim Cornall — Tue, 13 Sep 2022 09:01:03 +0000

Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […]

The post Starpharma announces new data for prostate cancer trial appeared first on Labiotech.eu.

License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East

Liza Laws — Thu, 01 Sep 2022 10:29:25 +0000

A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […]

The post License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East appeared first on Labiotech.eu.

Five emerging biotech hubs in the Asia-Pacific region

Omnia Ibrahim — Thu, 18 Aug 2022 22:02:18 +0000

The Asia-Pacific (APAC) region is the third largest pharmaceutical market in the world, and has seen a shift from predominantly producing generics to developing innovative technologies. Here are five emerging biotech hubs in the region to keep an eye on. The life sciences industry is seeing rapid growth in the APAC region – home to […]

The post Five emerging biotech hubs in the Asia-Pacific region appeared first on Labiotech.eu.